Abstract
Bioluminescence imaging has previously been used to monitor the formation of grafted tumors in vivo and measure cell number during tumor progression and response to therapy. The development and optimization of successful cancer therapy strategies may well require detailed and specific assessment of biological processes in response to mechanistic intervention. Here, we use bioluminescence imaging to monitor the cell cycle in a genetically engineered, histologically accurate model of glioma in vivo. In these platelet-derived growth factor (PDGF)-driven oligodendrogliomas, G1 cell-cycle arrest is generated by blockade of either the PDGF receptor or mTOR using small-molecule inhibitors.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cell Cycle / physiology*
-
Cell Cycle Proteins / genetics
-
DNA Primers
-
DNA-Binding Proteins / genetics
-
Disease Models, Animal*
-
E2F Transcription Factors
-
Immunohistochemistry
-
In Situ Nick-End Labeling
-
Luciferases / genetics
-
Luciferases / metabolism
-
Luminescent Measurements / methods*
-
Mice
-
Mice, Transgenic
-
Oligodendroglioma / metabolism
-
Oligodendroglioma / physiopathology*
-
Phthalazines / pharmacology
-
Platelet-Derived Growth Factor / metabolism*
-
Promoter Regions, Genetic / genetics
-
Protein Kinases / metabolism
-
Pyridines / pharmacology
-
Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors*
-
Receptor, Platelet-Derived Growth Factor alpha / metabolism
-
TOR Serine-Threonine Kinases
-
Transcription Factors / genetics
Substances
-
Cell Cycle Proteins
-
DNA Primers
-
DNA-Binding Proteins
-
E2F Transcription Factors
-
Phthalazines
-
Platelet-Derived Growth Factor
-
Pyridines
-
Transcription Factors
-
vatalanib
-
Luciferases
-
Protein Kinases
-
mTOR protein, mouse
-
Receptor, Platelet-Derived Growth Factor alpha
-
TOR Serine-Threonine Kinases